Compare Norfolk Southern Corporation (NSC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Sana Biotechnology Inc — how do they compare? Norfolk Southern Corporation trades at $335.84 (market cap $75.15B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Norfolk Southern Corporation is far larger — about 66.5× Sana Biotechnology Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NSC | SANA | |
|---|---|---|
Market Cap | $75.15B | $1.13B |
Sector | Technology | Health |
52-Week High | $350.66 | $5.92 |
52-Week Low | $272.35 | $2.68 |
Enterprise Value | $90.70B | $1.05B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.
The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
